USA flag logo/image

An Official Website of the United States Government

Processing Ac-227 sources for lead-212 and radium-223 required by cancer…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85406
Program Year/Program:
2007 / STTR
Agency Tracking Number:
CA124302
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ALPHAMED, INC
ALPHAMED, INC 150 Ellery Street Wrentham, MA 02093
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Processing Ac-227 sources for lead-212 and radium-223 required by cancer research
Agency: HHS
Contract: 1R41CA124302-01A1
Award Amount: $111,300.00
 

Abstract:

DESCRIPTION (provided by applicant): NIH sponsored cancer researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radi um-223 is being used in clinical trials in treatment of skeletal metastases. There is no effective therapy for these diseases. Together 199,280 people in the US will be diagnosed this year and 97,070 will die from these diseases (American Cancer Society 20 05 Cancer Facts and Figures). This promising cancer research must be supported with additional quantities of the isotope if this research is to proceed to later stage clinical trials and approved drug products. Also, additional amounts of the isotopes are required to support increased research on other cancers that will be undertaken as papers are published discussing the therapeutic effect achieved in current research. This grant application will increase the amount of these isotopes by processing and puri fying actinium-227, an isotope used in the production of neutron generators produced years ago and are now being disposed of. Two sources have been obtained, totaling 1.5 Ci. Actinium-227 once purified can be processed for Ra-223. It can also be irradiated to produce thorium-228, a precursor isotope to Pb-212. As a result of implementing this Phase I grant application, Ac-227 will be separated from these sources and separation techniques yielding high quality Ra-223 will be demonstrated. Additional sources of Ac-227 will be identified and candidate reactors for Ac-227 irradiations required for the production of Th-228 will be identified. As a result of implementing a Phase II grant, curie quantities of Ra-223 and Th-228/Pb-212 will be available at purity lev els required for medical research. -Relevance This Phase I grant application and a follow-on Phase II application proposes to increase the amount of radioisotopes required to support later stage research and anticipated approved drug products in therapies that are showing promise in cancer therapies. NIH funded researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radiu m-223 is being used in clinical trials in treatment of skeletal metastases.

Principal Investigator:

Chuck Z. Soderquist
5093763773
CHUCK.SODERQUIST@PNL.GOV

Business Contact:

Richard F. Testa
richard.testa@alphamed.biz
Small Business Information at Submission:

ALPHAMED, INC
ALPHAMED, INC 20 JUNIPER RIDGE RD ACTON, MA 01720

EIN/Tax ID: 043423769
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
PACIFIC NORTHWEST NATIONAL LAB
BATTELLE PACIFIC NORTHWEST LABS
BOX 999, 902 BATTELLE BLVD
RICHLAND, WA 99352 3364
RI Type: Federally funded R&D center (FFRDC)